Gregg L. Katz

Gregg Katz, a partner in Goodwin’s Technology group, works on a wide variety of public and private securities offerings, mergers and acquisitions, and other complex transactions. His practice centers on technology and life sciences companies, including clients in the software, artificial intelligence, hardware, biotechnology, pharmaceuticals, and other technology-driven industries.

Gregg’s representation of start-up and later-stage companies spans the entire corporate lifecycle, including pre-incorporation planning, venture capital financings, public offerings, SEC reporting and disclosure, mergers and acquisitions, and general corporate representation and counseling.

Gregg is a member of the firm’s Hiring and Pro Bono Committees.

Gregg’s transactional experience includes representing:

Public Offerings - Issuer

• Toast, the digital technology platform built for hospitality, in its $1.0 billion initial public offering on NYSE
• Moderna, a pioneer of mRNA therapeutics and vaccines, in its $604 million initial public offering on NASDAQ and in its $575 million and $1.3 billion follow-on offerings
• Enfusion, a leader in SaaS solutions for the investment management and hedge fund sectors, in its $367 million initial public offering on NYSE
• bluebird bio, a biotechnology company developing gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, in its $116 million initial public offering on NASDAQ and in eight follow-on public offerings totaling $3.5 billion
• Alnylam Pharmaceuticals, a leading RNAi therapeutics company, in four follow-on public offerings totaling $2.9 billion
• Aquaventure Holdings, a multinational provider of water-as-a-service solutions, in its $135 million initial public offering on NYSE and its $80 million follow-on offering
• Eloqua, a provider of on-demand revenue performance management software solutions, in its $106 million initial public offering on NASDAQ
• Omthera Pharmaceuticals, a pharmaceutical company focused on therapies for abnormalities in blood lipids and the treatment of cardiovascular disease, in its $64 million initial public offering on NASDAQ

Public Offerings - Underwriter

• J.P. Morgan, Goldman Sachs and Morgan Stanley in the $924 million initial public offering of Bright Health Group on NYSE
• Goldman Sachs and Morgan Stanley in the $300 million initial public offering of Blue Apron on NYSE
• Goldman Sachs and Credit Suisse in the $113 million initial public offering of Alarm.com on NASDAQ
• Goldman Sachs and Deutsche Bank in the $235 million and $344 million follow-on public offerings of CyberArk Software
• J.P. Morgan and Deutsche Bank in the $99 million initial public offering of CyberArk Software on NASDAQ
• Goldman Sachs and Credit Suisse in the $133 million initial public offering of 2U on NASDAQ and in three follow-on offerings totaling $688 million
• Stifel in the $57 million initial public offering of SPS Commerce on NASDAQ and in four follow-on offerings totaling $172 million

Private Financings

• 1X, an AI and robotics company, in multiple private financing rounds
• Dutchie, the technology platform powering cannabis commerce, in multiple private financing rounds
• Parabilis Medicines, a clinical-stage biopharmaceutical company, in its Series F financing
• Manifold, the AI platform of life sciences, in its Series B financing
• Toast, the digital technology platform built for hospitality, in multiple private financing rounds
• Salsify, the Commerce Experience Management platform empowering brand manufacturers, in multiple private financing rounds
• Circle Internet Financial, a digital currency company, in multiple private financing rounds
• Carrick Therapeutics, a clinical stage biopharmaceutical company, in multiple private financing rounds
• Carrot Fertility, a leading global fertility benefits provider for employers, in its Series D financing
• Alnylam Pharmaceuticals, a leading RNAi therapeutics company, in a $700 million equity financing closed in connection with Alnylam’s collaboration with Sanofi Genzyme, a $400 million equity financing closed in connection with Alnylam’s collaboration with Regeneron, and a $100 million equity financing closed in connection with Alnylam’s collaboration with Blackstone
• 2seventy bio, an immuno-oncology cell therapy company, in a $170 million PIPE financing
• OM1, a leading health outcomes and technology company, in multiple private financing rounds
• Encamp, an enterprise technology startup for environmental compliance data management and reporting, in its Series C financing
• Wellframe, a digital health management platform, in its Series C financing
• Bessemer Venture Partners in numerous portfolio company investments
• Marshall Wace in numerous portfolio company investments
• Optum Ventures in numerous portfolio company investments
• Seven Bridges Genomics in multiple private financing rounds
• Genomics Medicine Ireland, an Irish genomics research company, in its Series A financing
• TellusLabs, a leader in the use of satellite imaging for developing agricultural insights, in its seed financing

Mergers & Acquisitions

• Enfusion, a leader in SaaS solutions for the investment management and hedge fund sectors, in its sale to Clearwater Analytics
• 2seventy bio, a commercial stage biopharmaceutical company, in its sale to Bristol Myers Squibb
• Datavolo, an enterprise AI company, in its sale to Snowflake
• Symbotic, a leader in AI-enabled robotics technology for the supply chain, in its acquisitions of OhmniLabs and Veo Robotics
• Roman DBDR Technology Advisors in its acquisition of the Loyalty business from Bakkt
• Salsify, the Commerce Experience Management platform empowering brand manufacturers, in its acquisitions of Alkemics and SKUvantage
• Circle Internet Financial, a digital currency company, in the acquisition and subsequent spin-out of the Poloniex cryptocurrency trading platform and in the acquisition of SeedInvest
• Checkr, a technology platform for employment background checks, in its acquisition of GoodHire
• Toast, the digital technology platform built for hospitality, in its acquisition of Sling
• iRobot Corporation, a global consumer robot company in its acquisitions of Robopolis SAS, Evolution Robotics, Root Robotics and Aeris Cleantec, in the sale of its Defense & Security business to Arlington Capital Partners, and in the transition of its business through a bankruptcy proceeding to Picea
• Wellframe, a digital health management platform, in its sale to HealthEdge
• Roman DBDR Tech Acquisition Corp. in its business combination with CompoSecure
• Teva Pharmaceutical Industries, a leading global pharmaceutical company, in the sale of its specialty women’s global health business
• Neumora Therapeutics, a clinical-stage biotechnology company, in its acquisition of Blackthorn Therapeutics
• Genomics Medicine Ireland, an Irish genomics research company, in its sale to WuXi NextCODE
• Sansoro Health, a pioneer in data integration for health care, in its acquisition of Datica Health
• Cobalt Biomedicine, a biotechnology company, in its sale to Sana Biotechnology
• TellusLabs, a leader in the use of satellite imaging for developing agricultural insights, in its sale to Indigo Agriculture
• RedBrick Health, a health engagement and behavior-based technology company, in its sale to Marlin Equity Partners
• Code42 Software, a leader in cloud-based endpoint data protection and recovery, in the sale of its consumer business to Carbonite and in its sale to Mimecast
• Plex Systems, a leader in cloud ERP for manufacturing, in its acquisitions of DemandCaster, DATTUS and Kors Engineering
• bluebird bio, a biotechnology company developing gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, in its acquisition of Precision Genome Engineering
• Eloqua, a provider of on-demand revenue performance management software solutions, in its sale to Oracle Corporation
• Endeca Technologies, a provider of unstructured data management, web commerce and business intelligence solutions, in its sale to Oracle Corporation

Gregg is a member of the Massachusetts Bar Association and serves on the board of directors of the Hillel Council of New England. He was named the Youth Advocacy Foundation’s 2024 Pro Bono Attorney of the Year for his work with the EdLaw Foundation, supporting local students and their families since 2014. He also speaks at various industry events, including presenting on IPO preparedness at KPMG’s IPO Bootcamp from 2017–2025.

Gregg's speaking engagements have included:

• “Becoming a Public Company” at the 2017-2019 and 2021-2022 KPMG IPO Bootcamps
• “Preparing for Going Public: Lessons Learned from the 2021 Boom” sponsored by Deloitte